Volume | 597,303 |
|
|||||
News | - | ||||||
Day High | 15.19 | Low High |
|||||
Day Low | 14.10 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Arcus Biosciences Inc | RCUS | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
14.77 | 14.10 | 15.19 | 14.59 | 14.84 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
6,949 | 597,303 | US$ 14.51 | US$ 8,664,830 | - | 12.95 - 25.47 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:00:00 | 138,825 | US$ 14.59 | USD |
Arcus Biosciences (RCUS) Options Flow Summary
Arcus Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.33B | 90.86M | - | 117M | -307M | -3.38 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Arcus Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RCUS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 17.21 | 17.4994 | 14.10 | 15.45 | 586,550 | -2.62 | -15.22% |
1 Month | 17.15 | 19.11 | 14.10 | 16.95 | 602,037 | -2.56 | -14.93% |
3 Months | 15.45 | 20.31 | 14.10 | 17.37 | 840,467 | -0.86 | -5.57% |
6 Months | 16.14 | 20.31 | 12.95 | 16.83 | 807,913 | -1.55 | -9.60% |
1 Year | 18.44 | 25.47 | 12.95 | 18.41 | 876,482 | -3.85 | -20.88% |
3 Years | 32.68 | 49.10 | 12.95 | 24.53 | 851,181 | -18.09 | -55.35% |
5 Years | 10.97 | 49.10 | 6.30 | 24.26 | 680,824 | 3.62 | 33.00% |
Arcus Biosciences Description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. |